Edison Oncology is a clinical-stage biopharmaceutical company developing small-molecule cancer therapies. Edison's core strategy focuses on repurposing or reformulating drug compounds that prior developers abandoned, applying updated scientific understanding to target specific patient populations that were not the focus of original development efforts. Edison has four pipeline candidates: EO3001 (elesclomol), targeting cancers with ARID1A mutations; EO4426 (tezacitabine), targeting tumors resistant to approved RNR inhibitors; Orotecan, a proprietary oral formulation of the IV cancer drug irinotecan designed for pediatric oncology; and EO1001, an oral, brain-penetrant pan-ErbB inhibitor for solid tumors including brain cancer. All four are in Phase 1-2a trials. Edison has no approved products and no product revenue. The company's development approach is designed to reduce capital and time requirements: it relies on the FDA's 505(b)(2) NDA pathway, targets accelerated approval based on surrogate endpoints, conducts initial trials in Australia to benefit from faster startup and government R&D reimbursements of up to 43.5%, and holds options rather than outright ownership on two of its compounds. Manufacturing and clinical execution are fully outsourced. If products are eventually approved, Edison's long-term model would involve either direct commercialization or licensing to larger pharma companies, generating license fees, milestones, and royalties.